Balversa 3mg, 4mg and 5mg film-coated tablets

*
Pharmacy Only: Prescription
  • Company:

    Janssen Sciences Ireland (a Johnson & Johnson Company)
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    This medicinal product is subject to additional monitoring.

    *Additional information is available within the SPC or upon request to the company

qrcode image

Scan the QR code or enter an email to access and share this medicine:

Updated on 30 April 2026

File name

EN_IE-Balversa_SmPC_20260424_IA_EMA_VR_0000340655_Clean-approved_EDMS-ERI-137304389_42.0.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

EMA/VR/0000340655 - Type IA - PRAC Request for Growth Acceleration in Pediatrics

Updated on 30 April 2026

File name

EN_IE-Balversa_PIL_20260424_IA_EMA_VR_0000340655_Clean-approved_EDMS-ERI-137304389_42.0.pdf

Reasons for updating

  • Change to section 2 - use in children and adolescents
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

EMA/VR/0000340655 - Type IA - PRAC Request for Growth Acceleration in Pediatrics

Updated on 28 April 2025

File name

EN-IE-Balversa-20250218-PIL-IA-248998-Clean-approved (1).pdf

Reasons for updating

  • New PIL for new product

Free text change information supplied by the pharmaceutical company

PIL for launch: most recent procedure = EMA/VR/000248998 - removal blister + extra updates, approved 18 Feb 2025.

Updated on 28 April 2025

File name

IE-EN-Balversa-20250218-SmPC-IA-248998-Clean-approved (2).pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SmPC for launch: most recent procedure = EMA/VR/000248998 - removal blister + extra updates, approved 18 Feb 2025.

Janssen Sciences Ireland (a Johnson & Johnson Company)

Janssen Sciences Ireland (a Johnson & Johnson Company)